172,357 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Ruffer LLP

Ruffer LLP acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 172,357 shares of the company's stock, valued at approximately $7,982,000. Ruffer LLP owned approximately 0.32% of LivaNova as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its position in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Geode Capital Management LLC increased its position in LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after acquiring an additional 8,331 shares during the period. Victory Capital Management Inc. raised its stake in LivaNova by 16.6% during the 3rd quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock valued at $49,130,000 after acquiring an additional 133,401 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after purchasing an additional 93,311 shares during the last quarter. Finally, Paradice Investment Management LLC raised its stake in shares of LivaNova by 15.3% during the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock worth $22,545,000 after purchasing an additional 64,680 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

LivaNova Trading Down 1.3 %

Shares of LIVN stock traded down $0.51 during trading hours on Thursday, hitting $38.56. 616,612 shares of the company were exchanged, compared to its average volume of 641,886. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average of $46.32 and a 200 day moving average of $49.18. The firm has a market cap of $2.10 billion, a PE ratio of 91.81 and a beta of 1.10.

Analyst Ratings Changes

A number of equities research analysts recently commented on LIVN shares. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 26th. The Goldman Sachs Group lowered their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, Mizuho dropped their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.